COSCIENS Bio (CSCI) Enterprise Value to EBITDA Ratio

Public company logo of cosciensbio.com (CSCI)

COSCIENS Biopharma Inc. (CSCI) develops small-molecule therapies for rare pathologies, generating funding through grants and licenses. The EV/EBITDA valuation multiple reflects the current status of . The scaling model relies on transferring patents to corporate behemoths for royalties without incurring manufacturing plant costs. The strategic vector has shifted from legacy assets toward the expansion of an innovative clinical portfolio.

COSCIENS Biopharma Inc - CSCI Company Value to EBITDA (period 07/04/2022 - 11/10/2026)

Comprehensive metric breakdowns and analytics for cosciensbio.com (CSCI)

- current price and projected stock value:
Stock Price Aeterna Zentaris|CSCI - Analyst Median Target
- market capitalization details:
Market Valuation COSCIENS Bio|CSCI - Full Business Value
- business book valuation details:
Book Value per Share COSCIENS Biopharma|CSCI - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity COSCIENS Biopharma|CSCI - Company Aggregate Indebtedness|Debts to Book Capitalization COSCIENS Bio|CSCI - Company Long-Term Loans and Borrowings|Company Short-Term Debts COSCIENS Biopharma|Quick Liquidity cosciensbio.com
- financial results and valuation multiples details:
CSCI - Final Profit|Expected Profit COSCIENS Biopharma Inc.|CSCI - Price to Earnings Ratio|Forward P/E Multiple COSCIENS Biopharma Inc.|CSCI - PEG Multiple|EV/EBITDA Multiple COSCIENS Bio|CSCI - Operating profit before deduction of amortization|Earnings per share for the last twelve months COSCIENS Biopharma|CSCI - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cosciensbio.com|CSCI - Expected net earnings per share growth this year|Earnings growth forecast for next year COSCIENS Biopharma Inc.
Fundamental valuation:Aeterna Zentaris CSCI
Manufactured products of COSCIENS Biopharma

This indicator compares the total value of a company's assets and debts against its operating cash flow before taxes and depreciation. Analyzing the Enterprise Value to EBITDA ratio allows an investor to filter out market volatility, revealing whether a business is truly overvalued or undervalued. For COSCIENS Biopharma Inc. (CSCI), this metric confirms the efficiency of managing complex biologics logistics and the resilience of global distribution networks.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|Chemomab - EV/EBITDA Multiple|SRx Health Solutions Inc. (SRXH) - Enterprise Value to EBITDA Ratio|polyrizon-biotech.com (PLRZ) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Aeterna Zentaris Inc. (AEZS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclo Therapeutics|Inozyme (INZY) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RPHM